Jaypirca (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy (PRNewswire) - Sep 28, 2026 - "The approval is supported by data from the global Phase 3 BRUIN CLL-313 and BRUIN CLL-314 clinical trials."
China approval • Chronic Lymphocytic Leukemia • Small Lymphocytic Lymphoma
|